Related Experiment Videos
HER2 overexpression and cancer targeting
1Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Seminars in Oncology
|November 14, 2001
Summary
Overexpression of the HER2/neu oncogene drives poor prognosis in breast and ovarian cancers. Targeting this oncogene, its protein product, or its promoter offers promising therapeutic strategies for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- HER2/neu oncogene overexpression is common in breast and ovarian cancers.
- HER2/neu overexpression correlates with poor patient prognosis, increased relapse rates, and reduced survival.
Purpose of the Study:
- To discuss the biological signaling pathway mediated by the HER2/neu tyrosine kinase receptor.
- To address the mechanisms of transformation and tumorigenesis in HER2/neu-overexpressing cells.
- To summarize therapeutic strategies targeting HER2/neu in cancer treatment.
Main Methods:
- Review of biological signaling pathways.
- Analysis of tumorigenesis mechanisms.
- Summary of therapeutic strategies targeting HER2/neu.
Main Results:
- HER2/neu signaling pathways contribute to cancer development.
- Targeting HER2/neu expression can reverse malignancy.
- Strategies include targeting the p185 oncoprotein or transcriptional downregulation.
Conclusions:
- Targeting HER2/neu represents a clinically relevant strategy for cancer therapy.
- Fundamental studies support the potential of HER2/neu-targeted treatments.